Prelude Therapeutics Incorporated (PRLD) Financial Statements & Analysis

Prelude Therapeutics Incorporated (PRLD) Income Statement

Prelude Therapeutics Incorporated reported revenue of $12.14M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 73.4% from $7.00M a year earlier. Prelude Therapeutics Incorporated posted a net loss of $99.50M, compared with a net loss of $127.17M a year earlier. Gross margin was 100.0% and operating margin -861.3%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $5.70M.

Prelude Therapeutics Incorporated Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Prelude Therapeutics Incorporated income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	12.14	7.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	1.71	0.00	0.00	0.00	0.00	0.54	0.00	0.15
Gross Profit	12.14	7.00	0.00	0.00	0.00	-0.54	0.00	-0.15
Operating Expenses
Research & Development	93.10	118.00	103.39	92.89	86.78	48.18	24.28	12.62
Selling, General & Administrative	22.31	28.72	28.88	30.65	26.96	10.59	3.83	2.35
Operating Expenses	116.71	146.71	132.28	123.54	113.74	58.76	28.11	14.98
Operating Income	-104.57	-139.71	-132.28	-123.54	-113.74	-58.76	-28.11	-14.98
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	5.07	12.54	10.45	8.10	2.04	1.83	0.54	0.30
Income
Income Before Tax	-99.50	-127.17	-121.83	-115.44	-111.69	-56.93	-27.57	-14.68
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-99.50	-127.17	-121.83	-115.44	-111.69	-56.93	-27.57	-14.68
Net Income - Continuous Operations	-99.50	-127.17	-121.83	-115.44	-111.69	-56.93	-27.57	-14.68
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-
EBITDA	-101.56	-137.94	-131.11	-114.11	-110.78	-58.22	-27.73	-14.83
EBIT	-103.27	-139.71	-132.28	-123.54	-113.74	-58.76	-	-
Depreciation & Amortization	1.71	1.77	1.17	1.32	0.92	0.54	0.38	0.15
Earnings Per Share
Basic EPS	-1.00	-2.00	-2.00	-2.00	-2.00	-5.00	-1.00	-9.00
Diluted EPS	-1.00	-2.00	-2.00	-2.00	-2.00	-5.00	-1.00	-9.00
Basic Shares Outstanding	76.96	75.81	60.36	47.37	47.60	12.48	32.40	1.58
Diluted Shares Outstanding	76.96	75.81	60.36	47.37	47.60	12.48	32.40	1.58

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Prelude Therapeutics Incorporated Financial Statements

What was Prelude Therapeutics Incorporated's revenue in fiscal 2025?

Prelude Therapeutics Incorporated reported revenue of $12.14M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 73.4% from $7.00M a year earlier.

Is Prelude Therapeutics Incorporated profitable?

No. Prelude Therapeutics Incorporated reported a net loss of $99.50M in fiscal 2025. In fiscal 2024 it lost $127.17M.

What is Prelude Therapeutics Incorporated's operating margin?

Prelude Therapeutics Incorporated's operating income was −$104.57M on revenue of $12.14M in fiscal 2025, an operating margin of -861.3%, compared with -1995.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition